ReviewCureus2025
Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SGLT-2 Inhibitor use and liver-related and mortality outcomes in patients with type 2 diabetes and compensated cirrhosis.BMC medicine · 2026Article
- Correlation of Insulin and/or Insulin Secretagogues with the Risk of Hepatocellular Carcinoma and All-Cause Mortality Among Patients with Chronic Hepatitis B and Type 2 Diabetes Mellitus: A Retrospective Cohort Study.Journal of hepatocellular carcinoma · 2026Article
- Empagliflozin versus dapagliflozin in patients with liver cirrhosis: A comparative real-world study on hepatic decompensation.Hepatology forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cirrhosis, a progressive condition characterized by hepatic fibrosis and functional decline, remains a significant global health burden. Despite advancements in understanding its pathophysiology, effective therapies to halt or reverse progression are limited, especially in advanced stages. Cirrhosis decompensation represents an inflection point in the disease course, with a substantial increase in mortality. Ascites is the most common decompensating event, associated with significant morbidity and healthcare burden, making it a key target in the management of decompensated cirrhosis. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, widely used for type 2 diabetes mellitus, have demonstrated potential beyond glucose regulation. Evidence from clinical and preclinical studies suggests that SGLT2 inhibitors may improve hepatic parameters, reduce hepatic steatosis and fibrosis, and mitigate complications such as ascites. This review explores the multifaceted effects of SGLT2 inhibitors on cirrhosis, focusing on their mechanisms, clinical implications, and therapeutic potential in cirrhosis. By addressing current gaps in therapeutic strategies, SGLT2 inhibitors may represent a novel avenue for improving outcomes in patients with cirrhosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.